Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?

Table 1 Current stage of development of direct antiviral agents

Inhibitors of the NS3/4A serine protease
First-generation
Boceprevir	Approved
Telaprevir	Approved
Faldaprevir	Active clinical development
Sovaprevir	Active clinical development
Asunaprevir	Active clinical development
Simeprevir	Active clinical development
Danoprevir	Active clinical development
Vaniprevir	Active clinical development
Second-generation
MK-5172	Active clinical development
NS5A inhibitors
Daclatasvir	Advanced clinical development
GS-5885	Active clinical development
ABT-267	Active clinical development
PPI-461	Active clinical development
MK-8762	Active clinical development
NS5B polymerase inhibitors
Nucleos(t)ide inhibitors
Sofosbuvir	Advanced clinical development
Mericitabine	Active clinical development
ALS-2200	Active clinical development
Non-nucleos(t)ide inhibitors
Setrobuvir	Active clinical development
ABT-333	Active clinical development
GSK625433	Active clinical development